{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:13:18Z","timestamp":1781161998356,"version":"3.54.1"},"reference-count":64,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Philadelphia chromosome-negative myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia, and myelofibrosis. They are associated with increased thrombotic events, and the primary goal of therapy, in particular those with polycythemia vera and essential thrombocythemia, is the prevention of thrombotic complications typically with antiplatelet therapy and\/or cytoreduction. While several patient-, disease-, and genomic-related factors have been identified to influence thrombotic risks, there are no routine laboratory investigations to date that are sufficiently accurate to assess the underlying procoagulant state and predict the thrombotic risks. Conventional coagulation testing only measures time to clot formation and cannot reliably predict bleeding and thrombotic risks. Global coagulation assays such as thromboelastography, thrombin, and fibrin generation may provide a more thorough assessment of hemostatic function. Thromboelastography and thromboelastometry are viscoelastic tests which measure the mechanical properties of the hemostatic process, including the global dynamics of clot formation, stabilization, and dissolution. While viscoelastic testing is gaining traction in the investigations of coagulopathies and goal-directed blood product replacement in trauma and massive transfusion settings, the role of these assays in thrombosis is less well defined. Here, we provide a review of the current evidence of the role of viscoelastic testing in myeloproliferative neoplasm, particularly in the thrombotic risk assessment.<\/jats:p>","DOI":"10.1055\/s-0042-1753483","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T22:50:01Z","timestamp":1662159001000},"page":"173-181","source":"Crossref","is-referenced-by-count":4,"title":["Thrombosis Risk Assessment in Myeloproliferative Neoplasm\u2014Is There a Role for Viscoelastic Testing?"],"prefix":"10.1055","volume":"49","author":[{"given":"Hui Yin","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Northern Pathology Victoria, Northern Hospital, Epping VIC, Australia"},{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne VIC, Australia"},{"name":"Department of Medicine, Northern Health, University of Melbourne, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-7437","authenticated-orcid":false,"given":"Prahlad","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Northern Pathology Victoria, Northern Hospital, Epping VIC, Australia"},{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne VIC, Australia"},{"name":"Department of Medicine, Northern Health, University of Melbourne, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"issue":"20","key":"ref1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D A Arber","year":"2016","journal-title":"Blood"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"T Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"M A Elliott","year":"2005","journal-title":"Br J Haematol"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"E N Hamuly\u00e1k","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"R Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"F Lussana","year":"2009","journal-title":"Thromb Res"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.beha.2005.07.011","article-title":"Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention","volume":"19","author":"R Landolfi","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"E Rumi","year":"2017","journal-title":"Blood"},{"issue":"13","key":"ref9","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"T Barbui","year":"2013","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.tru.2021.100081","article-title":"Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective","volume":"5","author":"S Kelliher","year":"2021","journal-title":"Thromb Update"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"M Borowczyk","year":"2015","journal-title":"Thromb Res"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/cam4.2886","article-title":"Thrombosis among 1537 patients with JAK2V617F -mutated myeloproliferative neoplasms: risk factors and development of a predictive model","volume":"9","author":"Y Zhang","year":"2020","journal-title":"Cancer Med"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"P Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"D Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"G Rotunno","year":"2014","journal-title":"Blood"},{"issue":"04","key":"ref16","first-page":"CD006503","article-title":"Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia","volume":"4","author":"A Squizzato","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review","volume":"167","author":"D K Chu","year":"2017","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1538-7836.2007.02824.x","article-title":"Coagulation factors and the protein C system as determinants of thrombin generation in a normal population","volume":"6","author":"A W Dielis","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"e12657","DOI":"10.1002\/rth2.12657","article-title":"Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment","volume":"6","author":"T Barbui","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0038-1637750","article-title":"Direct oral anticoagulants and the paradigm shift in the management of venous thromboembolism","volume":"44","author":"H Y Lim","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"08","key":"ref21","doi-asserted-by":"crossref","first-page":"e0160046","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies","volume":"11","author":"L A Garc\u00eda Rodr\u00edguez","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.6004\/jnccn.2018.7073","article-title":"Do all patients with polycythemia vera or essential thrombocythemia need cytoreduction?","volume":"16","author":"K Sankar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"V De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"26","key":"ref24","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"T Barbui","year":"2012","journal-title":"Blood"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"P Guglielmelli","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2040620719870052","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"P Bose","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-030-20315-3_11","article-title":"Thrombosis in the Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"179","author":"K Sankar","year":"2019","journal-title":"Cancer Treat Res"},{"issue":"15","key":"ref28","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"J Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.thromres.2019.04.033","article-title":"A review of global coagulation assays\u2014is there a role in thrombosis risk prediction?","volume":"179","author":"H Y Lim","year":"2019","journal-title":"Thromb Res"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11239-021-02621-1","article-title":"Global coagulation assays in hypercoagulable states","volume":"54","author":"H Y Lim","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-13-1","article-title":"A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis","volume":"13","author":"M D Lanc\u00e9","year":"2015","journal-title":"Thromb J"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/00000539-200005000-00015","article-title":"The use of citrated whole blood in thromboelastography","volume":"90","author":"V A Bowbrick","year":"2000","journal-title":"Anesth Analg"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1213\/01.ANE.0000155290.86795.12","article-title":"Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction","volume":"100","author":"D J McCrath","year":"2005","journal-title":"Anesth Analg"},{"issue":"S 06","key":"ref34","first-page":"S1","article-title":"Basic principles of viscoelastic testing","volume":"60","author":"T Carll","year":"2020","journal-title":"Transfusion"},{"issue":"08","key":"ref35","first-page":"CD007871","article-title":"Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding","volume":"8","author":"A Wikkels\u00f8","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/1871529X17666171030120851","article-title":"A review of the current role of blood clotting analyzers in clinical practice","volume":"17","author":"K Sarode","year":"2017","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/s13054-014-0549-2","article-title":"Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery","volume":"18","author":"A Hincker","year":"2014","journal-title":"Crit Care"},{"issue":"S 06","key":"ref38","first-page":"S86","article-title":"Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): review of existing evidence, technology comparison, and clinical utility","volume":"60","author":"M Walsh","year":"2020","journal-title":"Transfusion"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1055\/s-0039-1688497","article-title":"Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: a review","volume":"45","author":"M Walsh","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000365652","article-title":"Thrombelastography maximal clot strength could predict one-year functional outcome in patients with ischemic stroke","volume":"38","author":"X Yao","year":"2014","journal-title":"Cerebrovasc Dis"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ejcts\/ezr001","article-title":"Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome","volume":"41","author":"S Rafiq","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1213\/ANE.0000000000001413","article-title":"A novel device for the evaluation of hemostatic function in critical care settings","volume":"123","author":"E A Ferrante","year":"2016","journal-title":"Anesth Analg"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00277-013-1834-x","article-title":"Global coagulation in myeloproliferative neoplasms","volume":"92","author":"A Tripodi","year":"2013","journal-title":"Ann Hematol"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MBC.0000000000000724","article-title":"An evaluation of global coagulation assays in myeloproliferative neoplasm","volume":"29","author":"H Y Lim","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MBC.0000000000000421","article-title":"Assessment of rotation thromboelastometry parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy","volume":"27","author":"J Treli\u0144ski","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/09537104.2020.1742309","article-title":"Use of rotational thromboelastometry for a global screening of coagulation profile in patients of myeloproliferative neoplasms","volume":"32","author":"D G \u015eahin","year":"2021","journal-title":"Platelets"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MBC.0000000000000088","article-title":"Selected parameters of hemostasis in patients with myeloproliferative neoplasms","volume":"25","author":"G Gadomska","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"04","key":"ref48","first-page":"684","article-title":"Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes","volume":"6","author":"D Ro\u015b\u0107","year":"2000","journal-title":"Med Sci Monit"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jamcollsurg.2018.03.031","article-title":"Utility of viscoelastic assays beyond coagulation: can preoperative thrombelastography indices predict tumor histology, nodal disease, and resectability in patients undergoing pancreatectomy?","volume":"227","author":"H B Moore","year":"2018","journal-title":"J Am Coll Surg"},{"key":"ref50","first-page":"103","article-title":"Correlation of hemostatic parameters with poly (ADP-ribose) olymerase-1 (PARP-1) polymorphisms, mutations, laboratory, and clinical characteristics in 114 patients with Philadelphia-negative myeloproliferative neoplasms","volume":"7","author":"N Giannakopoulou","year":"2021","journal-title":"J Hematol Blood Disord"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12185-008-0129-9","article-title":"Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2V617F mutation","volume":"88","author":"N Hattori","year":"2008","journal-title":"Int J Hematol"},{"issue":"10","key":"ref52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00277-014-2059-3","article-title":"Thromboelastometry changes in myeloproliferative neoplasms-surrogate for a procoagulant haemostatic imbalance or a consequence of technical reasons?: Comment on A. Tripodi et al. Ann Hematol (2013) 92:1633-1639","volume":"93","author":"M Nagler","year":"2014","journal-title":"Ann Hematol"},{"issue":"03","key":"ref53","first-page":"e103","article-title":"Global coagulation assays\u2014proposed reference intervals for healthy controls","volume":"44","author":"H Y Lim","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.thromres.2013.01.009","article-title":"Impact of changes in haematocrit level and platelet count on thromboelastometry parameters","volume":"131","author":"M Nagler","year":"2013","journal-title":"Thromb Res"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ajh.21974","article-title":"Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"M Panova-Noeva","year":"2011","journal-title":"Am J Hematol"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.23553","article-title":"Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis","volume":"88","author":"I Mignon","year":"2013","journal-title":"Am J Hematol"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3324\/haematol.2021.278499","article-title":"The possible role of mutated endothelial cells in myeloproliferative neoplasms","volume":"106","author":"M Farina","year":"2021","journal-title":"Haematologica"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/jpm12030364","article-title":"Circulating endothelial cell levels correlate with treatment outcomes of splanchnic vein thrombosis in patients with chronic myeloproliferative neoplasms","volume":"12","author":"G Giordano","year":"2022","journal-title":"J Pers Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000083844","article-title":"Virchow's triad revisited: blood constituents","volume":"33","author":"I Chung","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"S 01","key":"ref60","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S0049-3848(16)30159-1","article-title":"PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN)","volume":"140","author":"C Giaccherini","year":"2016","journal-title":"Thromb Res"},{"key":"ref61","first-page":"573","article-title":"Determinants of clot strength in polycythemia vera and primary myelofibrosis using rotational thromboelastometry","volume":"1","author":"N Nytofte","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"ref62","first-page":"266","article-title":"Thromboelastographic changes in patients with BCR-ABL negative myeloproliferative disorders","volume":"2","author":"M Cini","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"ref63","first-page":"465","article-title":"Investigating hemostasis in patients with newly diagnosed hematologic malignancies using a thromboelastography protocol","volume":"61","author":"W Liszewski","year":"2013","journal-title":"J Investig Med"},{"key":"ref64","first-page":"1129","article-title":"Essential thrombocythemia complicated with portal vein thrombosis and liver cirrhosis\u2014a case report","volume":"4","author":"N Petkova","year":"2020","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1753483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:19:21Z","timestamp":1675383561000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1753483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":64,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,2,2]]},"published-print":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1753483","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}